Emily Mullin is Associate Editor for Biomedicine at MIT Technology Review in Washington, D.C.
Segment
Read More
4:36
FDA Is Back On Board With A Breast Cancer Test
The FDA will now allow the consumer genetic testing company 23andMe to screen customers for mutations that boost breast cancer risk.